使用多巴胺系统稳定剂和精神兴奋剂联合治疗共病注意力缺陷多动障碍的持续性特发性面部疼痛：一例报告

Improvement in persistent idiopathic facial pain with comorbid ADHD using the combination of a dopamine system stabilizer and psychostimulant: A case report.

作者信息

Kasahara Satoshi, Kato Yuichi, Takahashi Kaori, Matsudaira Ko, Sato Naoko, Fukuda Ken-Ichi, Toyofuku Akira, Niwa Shin-Ichi, Uchida Kanji

机构信息

Department of Anesthesiology and Pain Relief Center The University of Tokyo Hospital Tokyo Japan.

Department of Pain Medicine Fukushima Medical University School of Medicine Fukushima Japan.

出版信息

Clin Case Rep. 2023 Jun 19;11(6):e7552. doi: 10.1002/ccr3.7552. eCollection 2023 Jun.

DOI:10.1002/ccr3.7552

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10279936/

Abstract

KEY CLINICAL MESSAGE

Persistent idiopathic facial pain (PIFP) and attention-deficit/hyperactivity disorder (ADHD) may coexist and can be improved with ADHD medications. Thus, clinicians should screen for ADHD by a multidisciplinary approach when treating PIFP and differentiate between other odontogenic disorders.

ABSTRACT

We report a case of a woman with persistent idiopathic facial pain (PIFP) and attention-deficit/hyperactivity disorder (ADHD) that markedly improved with the administration of a combination of aripiprazole (APZ) and methylphenidate (MP) treatment. Screening for ADHD and administration of APZ and/or MP may be considered in treating PIFP.

摘要

关键临床信息

持续性特发性面部疼痛（PIFP）与注意力缺陷多动障碍（ADHD）可能并存，且使用治疗ADHD的药物可使其得到改善。因此，临床医生在治疗PIFP时应采用多学科方法筛查ADHD，并与其他牙源性疾病相鉴别。

摘要

我们报告了一例患有持续性特发性面部疼痛（PIFP）和注意力缺陷多动障碍（ADHD）的女性病例，其在使用阿立哌唑（APZ）和哌甲酯（MP）联合治疗后有显著改善。在治疗PIFP时可考虑筛查ADHD并使用APZ和/或MP。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/657f/10279936/abfd957ac89a/CCR3-11-e7552-g004.jpg

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Improvement in persistent idiopathic facial pain with comorbid ADHD using the combination of a dopamine system stabilizer and psychostimulant: A case report.

Clin Case Rep. 2023 Jun 19;11(6):e7552. doi: 10.1002/ccr3.7552. eCollection 2023 Jun.

2

Diagnosis and treatment of intractable idiopathic orofacial pain with attention-deficit/hyperactivity disorder.

Sci Rep. 2023 Jan 30;13(1):1678. doi: 10.1038/s41598-023-28931-3.

3

Case Report: Methylphenidate and venlafaxine improved abdominal nociplastic pain in an adult patient with attention deficit hyperactivity disorder, autism spectrum disorder, and comorbid major depression.

Front Pain Res (Lausanne). 2024 Aug 21;5:1394131. doi: 10.3389/fpain.2024.1394131. eCollection 2024.

4

Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.

J Child Adolesc Psychopharmacol. 2018 Dec;28(10):682-689. doi: 10.1089/cap.2018.0068. Epub 2018 Aug 27.

5

Case report: Remission of chronic low back pain and oral dysesthesia comorbid with attention deficit/hyperactivity disorder by treatment with atomoxetine and pramipexole.

Front Pain Res (Lausanne). 2023 Jun 5;4:1159134. doi: 10.3389/fpain.2023.1159134. eCollection 2023.

6

Case Report: Guanfacine and methylphenidate improved chronic lower back pain in autosomal dominant polycystic kidney disease with comorbid attention deficit hyperactivity disorder and autism spectrum disorder.

Front Pediatr. 2023 Nov 1;11:1283823. doi: 10.3389/fped.2023.1283823. eCollection 2023.

7

Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD).

Pain Pract. 2015 Jan;15(1):4-11. doi: 10.1111/papr.12129. Epub 2013 Oct 18.

8

Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.

J Am Acad Child Adolesc Psychiatry. 2009 Sep;48(9):884-893. doi: 10.1097/CHI.0b013e3181b26e9f.

9

Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.

CNS Drugs. 2017 Nov;31(11):999-1014. doi: 10.1007/s40263-017-0468-2.

10

Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.

Cochrane Database Syst Rev. 2018 Jun 26;6(6):CD007990. doi: 10.1002/14651858.CD007990.pub3.

引用本文的文献

1

Recognition and treatment of attention deficit-hyperactivity disorder in patients with treatment-resistant burning mouth syndrome: a retrospective case study.

Front Pain Res (Lausanne). 2025 Apr 23;6:1536584. doi: 10.3389/fpain.2025.1536584. eCollection 2025.

2

Correlation between attention deficit/hyperactivity disorder and chronic pain: a survey of adults in Japan.

Sci Rep. 2025 Apr 16;15(1):13165. doi: 10.1038/s41598-025-95864-4.

3

Innovative therapeutic strategies using ADHD medications tailored to the behavioral characteristics of patients with chronic pain.

Front Pharmacol. 2025 Feb 26;16:1500313. doi: 10.3389/fphar.2025.1500313. eCollection 2025.

4

Precuneal hyperperfusion in patients with attention-deficit/hyperactivity disorder-comorbid nociplastic pain.

Front Pharmacol. 2024 Oct 17;15:1480546. doi: 10.3389/fphar.2024.1480546. eCollection 2024.

5

Case Report: Methylphenidate and venlafaxine improved abdominal nociplastic pain in an adult patient with attention deficit hyperactivity disorder, autism spectrum disorder, and comorbid major depression.

Front Pain Res (Lausanne). 2024 Aug 21;5:1394131. doi: 10.3389/fpain.2024.1394131. eCollection 2024.

6

Reappraising the psychosomatic approach in the study of "chronic orofacial pain": looking for the essential nature of these intractable conditions.

Front Pain Res (Lausanne). 2024 May 10;5:1349847. doi: 10.3389/fpain.2024.1349847. eCollection 2024.

7

Case Report: Guanfacine and methylphenidate improved chronic lower back pain in autosomal dominant polycystic kidney disease with comorbid attention deficit hyperactivity disorder and autism spectrum disorder.

Front Pediatr. 2023 Nov 1;11:1283823. doi: 10.3389/fped.2023.1283823. eCollection 2023.

本文引用的文献

1

Diagnosis and treatment of intractable idiopathic orofacial pain with attention-deficit/hyperactivity disorder.

Sci Rep. 2023 Jan 30;13(1):1678. doi: 10.1038/s41598-023-28931-3.

2

Attention-Deficit/hyperactivity disorder and centralized pain: A review of the case of John F. Kennedy.

Clin Case Rep. 2022 Oct 8;10(10):e6422. doi: 10.1002/ccr3.6422. eCollection 2022 Oct.

3

Case report: Treatment of persistent atypical odontalgia with attention deficit hyperactivity disorder and autism spectrum disorder with risperidone and atomoxetine.

Front Pain Res (Lausanne). 2022 Jul 22;3:926946. doi: 10.3389/fpain.2022.926946. eCollection 2022.

4

High Attention-Deficit/Hyperactivity Disorder Scale Scores Among Patients with Persistent Chronic Nonspecific Low Back Pain.

Pain Physician. 2021 May;24(3):E299-E307.

5

Pain and Attention-Deficit/Hyperactivity Disorder: The Case of Margaret Mitchell.

Psychosom Med. 2021 Jun 1;83(5):492-493. doi: 10.1097/PSY.0000000000000947.

6

Idiopathic Facial Pain Syndromes–An Overview and Clinical Implications.

Dtsch Arztebl Int. 2021 Feb 12;118(6):81-87. doi: 10.3238/arztebl.m2021.0006.

7

Attention-Deficit/Hyperactivity Disorder and Chronic Pain.

Psychosom Med. 2020 Apr;82(3):346-347. doi: 10.1097/PSY.0000000000000789.

8

Clinically significant changes in pain along the Pain Intensity Numerical Rating Scale in patients with chronic low back pain.

PLoS One. 2020 Mar 3;15(3):e0229228. doi: 10.1371/journal.pone.0229228. eCollection 2020.

9

International Classification of Orofacial Pain, 1st edition (ICOP).

Cephalalgia. 2020 Feb;40(2):129-221. doi: 10.1177/0333102419893823.

10

Attention-deficit hyperactivity disorder and impulsivity in female patients with fibromyalgia.

Neuropsychiatr Dis Treat. 2018 Jul 24;14:1883-1889. doi: 10.2147/NDT.S159312. eCollection 2018.